DPIIT collaborate with Pfizer to strengthen India healthcare innovation ecosystem
New Delhi: In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.
The collaboration aims to accelerate the lab-to-market journey of innovative healthcare products by extending both financial and non-financial support to startups.
Under the partnership, the Pfizer INDovation program will empower DPIIT-recognized startups with grants of up to Rs 60 lakhs each, along with a tailored 18-month incubation program delivered by Social Alpha. The program will provide dedicated acceleration tracks covering clinical validation, regulatory approvals, and go-to-market strategies. Startups will also gain access to expert mentorship, infrastructure, and global networks, in addition to exposure at Pfizer’s Research and Development facilities in Chennai, enabling them to strengthen innovations with advanced industry insights.
In July, Pfizer received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct Phase III clinical trial of the Respiratory Syncytial Virus Perfusion F Subunit Vaccine. However, this approval is subjected to the condition that the firm should specify the number of subjects with preexisting stable disease.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.